JNJ’s subcutaneous Tremfya demonstrates efficacy in Crohn’s
by
Contributor since / Followers
Contributor since / Followers
2 months ago
JHVEPhoto/iStock Editorial via Getty Images
- A phase 3 study found that a subcutaneous version of Johnson & Johnson’s Tremfya (guselkumab) was effective in treating Crohn’s disease.
- Data from the GRAVITI study showed that the SC version of the IL-23 inhibitor led to significant clinical remission and endoscopic response at 48 weeks.
- At 12 weeks, endoscopic response was seen in 41.3 % of patients on SC Tremfya compared to 21.4% in the placebo group.
- At 48 weeks, endoscopic response was achieved in 44.3% and 51.3% of patients in the Tremfya 100 mg SC every eight weeks group and 200 mg SC every four weeks group, respectively, compared to 6.8% in the placebo group.